glp-1 forum Exploring New Frontiers in Nutrition and Metabolic Health at the UC Davis Discovery GLP-1 anti-obesity medicines remain too
Description
The former world No.1 has a partnership with Ro and uses the weight-loss drug Zepbound, which is currently being monitored by WADA.
The FDA recently approved versions of GLP-1 medication - including Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) - for chronic weight management
The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7%
Mounjaro hit $23 billion, and Zepbound added $13.5 billion
